Janux Therapeutics, Inc. (JANX)
NASDAQ: JANX · Real-Time Price · USD
51.99
-0.85 (-1.61%)
Nov 13, 2024, 4:00 PM EST - Market closed
Janux Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Revenue | 13.05 | 8.08 | 8.61 | 3.64 | - | - |
| Revenue Growth (YoY) | 54.12% | -6.14% | 136.79% | - | - | - |
| Cost of Revenue | 59.82 | 54.92 | 53.44 | 26.24 | 3.04 | - |
| Gross Profit | -46.77 | -46.84 | -44.83 | -22.6 | -3.04 | - |
| Selling, General & Admin | 39.19 | 26.14 | 22.26 | 10.33 | 1.8 | 0.77 |
| Research & Development | - | - | - | - | - | 3 |
| Operating Expenses | 39.19 | 26.14 | 22.26 | 10.33 | 1.8 | 3.77 |
| Operating Income | -85.96 | -72.98 | -67.09 | -32.93 | -4.84 | -3.77 |
| Interest Expense | - | - | - | - | -0.21 | -0.23 |
| Interest & Investment Income | 25.43 | 14.69 | 4.03 | 0.26 | - | - |
| EBT Excluding Unusual Items | -60.54 | -58.29 | -63.06 | -32.67 | -5.05 | -4 |
| Other Unusual Items | - | - | - | - | -1.74 | - |
| Pretax Income | -60.54 | -58.29 | -63.06 | -32.67 | -6.78 | -4 |
| Net Income | -60.54 | -58.29 | -63.06 | -32.67 | -6.78 | -4 |
| Net Income to Common | -60.54 | -58.29 | -63.06 | -32.67 | -6.78 | -4 |
| Shares Outstanding (Basic) | 51 | 44 | 41 | 24 | 1 | 1 |
| Shares Outstanding (Diluted) | 51 | 44 | 41 | 24 | 1 | 1 |
| Shares Change (YoY) | 19.85% | 6.14% | 76.24% | 2471.20% | 36.71% | - |
| EPS (Basic) | -1.18 | -1.32 | -1.52 | -1.39 | -7.41 | -5.98 |
| EPS (Diluted) | -1.19 | -1.32 | -1.52 | -1.39 | -7.41 | -5.98 |
| Free Cash Flow | -37.82 | -52.43 | -49.37 | -18.46 | -4.37 | -3.83 |
| Free Cash Flow Per Share | -0.74 | -1.19 | -1.19 | -0.78 | -4.77 | -5.72 |
| Operating Margin | -658.76% | -902.87% | -779.04% | -905.39% | - | - |
| Profit Margin | -463.91% | -721.18% | -732.22% | -898.32% | - | - |
| Free Cash Flow Margin | -289.85% | -648.58% | -573.24% | -507.51% | - | - |
| EBITDA | -83.88 | -71.02 | -66.25 | -32.82 | -4.83 | -3.77 |
| D&A For EBITDA | 2.08 | 1.96 | 0.84 | 0.11 | 0.01 | 0.01 |
| EBIT | -85.96 | -72.98 | -67.09 | -32.93 | -4.84 | -3.77 |
Source: S&P Capital IQ. Standard template.
Financial Sources.